InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,880.00
(
-2.30%
)
Dow Jones
43,444.99
(
-0.70%
)
Brent Oil
70.90
(
0.00%
)
Bitcoin
91,381.85
(
0.35%
)

Replies to post #48765 on Biotech Values

Replies to #48765 on Biotech Values
icon url

rfj1862

06/20/07 4:59 PM

#48766 RE: DewDiligence #48765

This news makes other TLR companies great shorts.
icon url

friendofthedevil

06/20/07 5:21 PM

#48769 RE: DewDiligence #48765

COLY

They also left open the door for breast and malignant melanoma trials to continue. It is entirely up to PFE...

I am well aware of "program-survival bias" but I am more disappointed than usual here; not because of the double-blinding of the Ph II as much as because of the PFE due diligence. They paid a lot for 676. COLY is essentially selling for cash now, though, that is before the 20 mill for the 3M TLR patents is spent.